Phase II Study of Ponatinib in Advanced Lung and Head and Neck Cancers With FGFR Kinase Alterations

Trial Profile

Phase II Study of Ponatinib in Advanced Lung and Head and Neck Cancers With FGFR Kinase Alterations

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 30 Dec 2014

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Dec 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 18 Oct 2013 Status changed from recruiting to suspended according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top